Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs Li Auto Inc (LI) Price & Performance

Ginkgo Bioworks Holdings IncTrade
Li Auto IncTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs Li Auto Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.1 (market cap $590.53M), while Li Auto Inc trades at $12.7 (market cap $12.25B). The key difference: Li Auto Inc is far larger — about 20.7× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.

DNALI
Market Cap
$590.53M$12.25B
Sector
HealthConsumer Cyclical
52-Week High
$16.14$31.80
52-Week Low
$5.48$11.74
Enterprise Value
$627.78M$1.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.

The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.

Li Auto Inc

Li Auto (LI) trades at $12.18, down 0.66% on the day, with a bearish technical signal and mixed earnings history. The company reported a net income margin of -1.66% for 2025 and faces headwinds from domestic competition and aggressive discounting. Recent news highlights delivery updates and new model launches, but the stock remains under pressure amid broader EV sector challenges.

The outlook is cautious with a consensus price target of $14.80, suggesting potential upside, but risks include profitability concerns, competitive pressures, and volatile cash flows. Recovery hinges on successful execution of the L series and global expansion, with FY2025-2026 seen as trough years before potential improvement from 2027.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA

About Li Auto Inc

Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.

Read more on LI